{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:44:52Z","timestamp":1792115092307,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaci.2026.04.028","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:44:06Z","timestamp":1779752646000},"page":"857-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis: STEPIn mechanistic substudy results"],"prefix":"10.1016","volume":"158","author":[{"given":"Johann E.","family":"Gudjonsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swann","family":"Gaulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam C.","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Cardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal K.","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Coon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaanika","family":"K\u00e4rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv","family":"Eidsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Jagiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kolbinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-3440","authenticated-orcid":false,"given":"Curdin","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10281","key":"10.1016\/j.jaci.2026.04.028_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.04.028_bib2","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1038\/ncomms8001","article-title":"Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci","volume":"6","author":"Tsoi","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.04.028_bib3","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2026.04.028_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.04.028_bib5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ng.694","article-title":"A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1","volume":"42","author":"Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2026.04.028_bib6","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/ng.690","article-title":"Association analyses identify six new psoriasis susceptibility loci in the Chinese population","volume":"42","author":"Sun","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2026.04.028_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.04.028_bib8","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.04.028_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"10275","key":"10.1016\/j.jaci.2026.04.028_bib10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.04.028_bib11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.jid.2018.02.030","article-title":"Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome","volume":"138","author":"Gallais Serezal","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2340\/00015555-3233","article-title":"Non-random plaque-site recurrence of psoriasis in patients treated with Dead Sea climatotherapy","volume":"99","author":"Emmanuel","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2026.04.028_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00281-019-00766-z","article-title":"Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)","volume":"41","author":"Benezeder","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2026.04.028_bib14","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2026.04.028_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"7677","key":"10.1016\/j.jaci.2026.04.028_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature24271","article-title":"Inflammatory memory sensitizes skin epithelial stem cells to tissue damage","volume":"550","author":"Naik","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2026.04.028_bib17","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.stem.2021.07.001","article-title":"Establishment, maintenance, and recall of inflammatory memory","volume":"28","author":"Larsen","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jaci.2026.04.028_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-18404-9","article-title":"RNA-Seq identifies a diminished differentiation gene signature in primary monolayer keratinocytes grown from lesional and uninvolved psoriatic skin","volume":"7","author":"Swindell","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2026.04.028_bib19","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u201cclinical super response\u201d): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Schakel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.028_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13555-019-0310-5","article-title":"Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15-year single-center experience","volume":"9","author":"Huang","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2026.04.028_bib21","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1111\/jdv.16809","article-title":"Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study","volume":"35","author":"Rivera","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.028_bib22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.18846","article-title":"Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study","volume":"37","author":"Iversen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.028_bib23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/jdv.14979","article-title":"Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification\u2014rationale and design of the randomized, multicenter STEPIn study","volume":"32","author":"Iversen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.04.028_bib24","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib25","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/MCB.20.4.1436-1447.2000","article-title":"Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics","volume":"20","author":"Dickson","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jaci.2026.04.028_bib42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.04.028_bib26","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib27","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2021.07.024","article-title":"Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"7057","key":"10.1016\/j.jaci.2026.04.028_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature03963","article-title":"Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins","volume":"437","author":"Zenz","year":"2005","journal-title":"Nature"},{"issue":"3 pt 1","key":"10.1016\/j.jaci.2026.04.028_bib29","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/jid.2011.348","article-title":"A subset of methylated CpG sites differentiate psoriatic from normal skin","volume":"132","author":"Roberson","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s43587-021-00051-5","article-title":"Common genetic associations between age-related diseases","volume":"1","author":"D\u00f6nerta\u015f","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.jaci.2026.04.028_bib31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.micinf.2014.08.005","article-title":"Transcriptional regulation of CCL20 expression","volume":"16","author":"Zhao","year":"2014","journal-title":"Microbes Infect"},{"key":"10.1016\/j.jaci.2026.04.028_bib32","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/jid.2013.237","article-title":"IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis","volume":"133","author":"Wang","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/ced\/llad329","article-title":"Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase 3 studies","volume":"49","author":"Lebwohl","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40257-023-00801-8","article-title":"Do biologic treatments for psoriasis lower the risk of psoriatic arthritis? A systematic review","volume":"24","author":"Aronovich","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1006\/bbrc.2000.3743","article-title":"Small GTPase Rac1: structure, localization, and expression of the human gene","volume":"277","author":"Matos","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2026.04.028_bib36","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1172\/JCI85738","article-title":"RAC1 activation drives pathologic interactions between the epidermis and immune cells","volume":"126","author":"Winge","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.04.028_bib37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nm1605","article-title":"Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis","volume":"13","author":"Conrad","year":"2007","journal-title":"Nat Med"},{"issue":"7980","key":"10.1016\/j.jaci.2026.04.028_bib38","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41586-023-06546-y","article-title":"Reductive carboxylation epigenetically instructs T cell differentiation","volume":"621","author":"Jaccard","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2026.04.028_bib39","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.immuni.2023.05.003","article-title":"Human skin-resident CD8+ T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49a","volume":"56","author":"Zitti","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2026.04.028_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2133.1991.tb14774.x","article-title":"Psoriasis induced by interferon-alpha","volume":"125","author":"Funk","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2026.04.028_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926003672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926003672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:51:56Z","timestamp":1792111916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926003672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0091674926003672"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.04.028","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis: STEPIn mechanistic substudy results","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}